CNS manifestations of Fabry's disease

Garman, 2004, The molecular defect leading to Fabry disease: structure of human alpha-galactosidase, J Mol Biol, 337, 319, 10.1016/j.jmb.2004.01.035 Mehta, 2004, Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry outcome survey, Eur J Clin Invest, 34, 236, 10.1111/j.1365-2362.2004.01309.x Mitsias, 1996, Cerebrovascular complications of Fabry's disease, Ann Neurol, 40, 8, 10.1002/ana.410400105 Ginsberg, 2006, Magnetic resonance imaging changes in Fabry disease, Acta Paediatr Suppl, 95, 57, 10.1080/08035320600618908 Lehmann, 2006, A 32-year-old man with relapsing-progressive brainstem symptoms, Lancet Neurol, 5, 97, 10.1016/S1474-4422(05)70287-8 Mehta, 2005, Natural history of the cerebrovascular complications of Fabry disease, Acta Paediatr Suppl, 94, 24, 10.1080/08035320510028076 Lyon, 1961, Gene action in the X-chromosome of the mouse (Mus musculus L), Nature, 190, 372, 10.1038/190372a0 Morgan, 1990, The neurological complications of Anderson-Fabry disease (alpha-galactosidase A deficiency): investigation of symptomatic and presymptomatic patients, Q J Med, 75, 491 Crutchfield, 1998, Quantitative analysis of cerebral vasculopathy in patients with Fabry disease, Neurology, 50, 1746, 10.1212/WNL.50.6.1746 Tedeschi, 1999, Diffuse central neuronal involvement in Fabry disease: a proton MRS imaging study, Neurology, 52, 1663, 10.1212/WNL.52.8.1663 Moore, 2002, Elevated CNS average diffusion constant in Fabry disease, Acta Paediatr Suppl, 91, 67, 10.1111/j.1651-2227.2002.tb03114.x Takanashi, 2003, T1 hyperintensity in the pulvinar: key imaging feature for diagnosis of Fabry disease, AJNR Am J Neuroradiol, 24, 916 Moore, 2003, Increased signal intensity in the pulvinar on T1-weighted images: a pathognomonic MR imaging sign of Fabry disease, AJNR Am J Neuroradiol, 24, 1096 Moore, 2003, White matter lesions in Fabry disease occur in ‚prior’ selectively hypometabolic and hyperperfused brain regions, Brain Res Bull, 62, 231, 10.1016/j.brainresbull.2003.09.021 Jardim, 2004, CNS involvement in Fabry disease: clinical and imaging studies before and after 12 months of enzyme replacement therapy, J Inherit Metab Dis, 27, 229, 10.1023/B:BOLI.0000028794.04349.91 Fellgiebel, 2005, White matter lesion severity in male and female patients with Fabry disease, Neurology, 65, 600, 10.1212/01.wnl.0000173030.70057.eb Fellgiebel, 2006, Pattern of microstructural brain tissue alterations in Fabry disease: a diffusion-tensor imaging study, J Neurol, 253, 780, 10.1007/s00415-006-0118-y Gupta, 2005, The relationship of vascular glycolipid storage to clinical manifestations of fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women, Medicine (Baltimore), 84, 261, 10.1097/01.md.0000178976.62537.6b Politei, 2006, Magnetic resonance image findings in 5 young patients with Fabry disease, Neurologist, 12, 103, 10.1097/01.nrl.0000187495.16824.a6 Marino, 2006, Diffuse structural and metabolic brain changes in Fabry disease, J Neurol, 10.1007/s00415-005-0020-z Cabrera-Salazar, 2005, Radiological evidence of early cerebral microvascular disease in young children with Fabry disease, J Pediatr, 147, 102, 10.1016/j.jpeds.2005.03.004 Hilz, 2004, Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease, J Neurol, 251, 564, 10.1007/s00415-004-0364-9 Itoh, 2001, Local and global cerebral blood flow and glucose utilization in the alpha-galactosidase A knockout mouse model of Fabry disease, J Neurochem, 79, 1217, 10.1046/j.1471-4159.2001.00669.x Pantoni, 1997, Pathogenesis of leukoaraiosis: a review, Stroke, 28, 652, 10.1161/01.STR.28.3.652 Bisschops, 2004, High total cerebral blood flow is associated with a decrease of white matter lesions, J Neurol, 251, 1481, 10.1007/s00415-004-0569-y Shibata, 2004, White matter lesions and glial activation in a novel mouse model of chronic cerebral hypoperfusion, Stroke, 35, 2598, 10.1161/01.STR.0000143725.19053.60 Altarescu, 2005, Effect of genetic modifiers on cerebral lesions in Fabry disease, Neurology, 64, 2148, 10.1212/01.WNL.0000166000.24321.4F Hughes, 2005, Vascular complications of Fabry disease: enzyme replacement and other therapies, Acta Paediatr Suppl, 94, 28, 10.1080/08035320510028760 Garzuly, 2005, Megadolichobasilar anomaly with thrombosis in a family with Fabry's disease and a novel mutation in the alpha-galactosidase A gene, Brain, 128, 2078, 10.1093/brain/awh546 deVeber, 1992, Fabry disease: immunocytochemical characterization of neuronal involvement, Ann Neurol, 31, 409, 10.1002/ana.410310410 Kaye, 1988, Nervous system involvement in Fabry's disease: clinicopathological and biochemical correlation, Ann Neurol, 23, 505, 10.1002/ana.410230513 Schiffmann, 2006, Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement, Virchows Arch, 448, 337, 10.1007/s00428-005-0089-x Rolfs, 2005, Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study, Lancet, 366, 1794, 10.1016/S0140-6736(05)67635-0 Carolei, 1993, A prospective study of cerebral ischemia in the young. Analysis of pathogenic determinants, Stroke, 24, 362, 10.1161/01.STR.24.3.362 Kristensen, 1997, Epidemiology and etiology of ischemic stroke in young adults aged 18 to 44 years in northern Sweden, Stroke, 28, 1702, 10.1161/01.STR.28.9.1702 Adams, 1995, Ischemic stroke in young adults: experience in 329 patients enrolled in the Iowa Registry of stroke in young adults, Arch Neurol, 52, 491, 10.1001/archneur.1995.00540290081021 Yamauchi, 2002, Significance of white matter high intensity lesions as a predictor of stroke from arteriolosclerosis, J Neurol Neurosurg Psychiatry, 72, 576, 10.1136/jnnp.72.5.576 Prins, 2004, Measuring progression of cerebral white matter lesions on MRI: visual rating and volumetrics, Neurology, 62, 1533, 10.1212/01.WNL.0000123264.40498.B6 Holtmannspotter, 2005, Diffusion magnetic resonance histograms as a surrogate marker and predictor of disease progression in CADASIL: a two-year follow-up study, Stroke, 36, 2559, 10.1161/01.STR.0000189696.70989.a4 O'Sullivan, 2001, Normal-appearing white matter in ischemic leukoaraiosis: a diffusion tensor MRI study, Neurology, 57, 2307, 10.1212/WNL.57.12.2307 O'Sullivan, 2004, Diffusion tensor MRI correlates with executive dysfunction in patients with ischaemic leukoaraiosis, J Neurol Neurosurg Psychiatry, 75, 441, 10.1136/jnnp.2003.014910 DeGraba, 2000, Profile of endothelial and leukocyte activation in Fabry patients, Ann Neurol, 47, 229, 10.1002/1531-8249(200002)47:2<229::AID-ANA13>3.0.CO;2-T Demuth, 2002, Endothelial markers and homocysteine in patients with classic Fabry disease, Acta Paediatr Suppl, 91, 57, 10.1111/j.1651-2227.2002.tb03112.x Beck, 2004, Fabry disease: overall effects of agalsidase alfa treatment, Eur J Clin Invest, 34, 838, 10.1111/j.1365-2362.2004.01424.x Hilz, 2004, Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy, Neurology, 62, 1066, 10.1212/01.WNL.0000118207.84514.40 Moore, 2002, Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement, Stroke, 33, 525, 10.1161/hs0202.102601